PL1819230T3 - Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia - Google Patents

Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia

Info

Publication number
PL1819230T3
PL1819230T3 PL05849361T PL05849361T PL1819230T3 PL 1819230 T3 PL1819230 T3 PL 1819230T3 PL 05849361 T PL05849361 T PL 05849361T PL 05849361 T PL05849361 T PL 05849361T PL 1819230 T3 PL1819230 T3 PL 1819230T3
Authority
PL
Poland
Prior art keywords
microparticles
derived
hemorrhage
treatment
control
Prior art date
Application number
PL05849361T
Other languages
English (en)
Inventor
Wenche Jy
Joaquin J Jimenez
Lawrence L Horstmann
Yeon S Ahn
Eugene Ahn
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of PL1819230T3 publication Critical patent/PL1819230T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05849361T 2004-12-07 2005-12-07 Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia PL1819230T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63341704P 2004-12-07 2004-12-07
PCT/US2005/044064 WO2006062945A2 (en) 2004-12-07 2005-12-07 Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders
EP05849361A EP1819230B1 (en) 2004-12-07 2005-12-07 Red cell-derived microparticles as hemostatic agents for the control of hemorrhage and for treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
PL1819230T3 true PL1819230T3 (pl) 2013-02-28

Family

ID=36578476

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05849361T PL1819230T3 (pl) 2004-12-07 2005-12-07 Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia

Country Status (9)

Country Link
US (1) US8105632B2 (pl)
EP (1) EP1819230B1 (pl)
JP (1) JP5204490B2 (pl)
AT (1) ATE555799T1 (pl)
DK (1) DK1819230T3 (pl)
ES (1) ES2390317T3 (pl)
PL (1) PL1819230T3 (pl)
PT (1) PT1819230E (pl)
WO (1) WO2006062945A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155764B1 (en) * 2004-12-07 2015-10-13 University Of Miami Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
HUE025555T2 (en) 2007-02-07 2016-02-29 Univ California Conjugates and applications of synthetic tlr agonists
FR2917172B1 (fr) * 2007-06-07 2014-01-03 Inst Nat Sante Rech Med Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation
US20090062233A1 (en) * 2007-08-09 2009-03-05 Xin Ji Modified starch material of biocompatible hemostasis
JP2012531605A (ja) * 2009-07-01 2012-12-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心血管死亡率リスクを予測するための方法
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
NO2668262T3 (pl) * 2011-01-28 2018-04-28
JP2012168012A (ja) * 2011-02-14 2012-09-06 Nippon Koden Corp 血管内皮障害を検査するための新規な検査方法および検査用キット
WO2012135032A2 (en) * 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
WO2015069897A1 (en) * 2013-11-07 2015-05-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Red blood cell membrane-derived microparticles and their use for the treatment of lung disease
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
US10538738B2 (en) * 2014-05-19 2020-01-21 Eleftherios Papoutsakis Megakaryocytic particles and microparticles for cell therapy and fate modification of stem and progenitor cells
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
CN107405391B (zh) 2015-03-04 2021-03-19 罗切斯特大学 治疗外伤患者中的出血的血小板微粒的全身和局部应用
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017062422A1 (en) * 2015-10-07 2017-04-13 The Research Foundation For The State University Of New York METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXβ REDUCTASE
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
JP6896516B2 (ja) * 2016-07-25 2021-06-30 シスメックス株式会社 血液分析装置および血液分析方法
PT3548092T (pt) * 2016-11-30 2022-08-09 Univ Miami Composição rmp e métodos de uso
EP3601521A2 (en) 2017-03-31 2020-02-05 Terumo BCT, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2024104456A1 (zh) * 2022-11-18 2024-05-23 中山大学 囊泡在制备体外促凝血或体外止血药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941031D1 (de) 1998-11-12 2009-08-06 Novolytics Inc Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion

Also Published As

Publication number Publication date
EP1819230A2 (en) 2007-08-22
EP1819230A4 (en) 2009-08-12
PT1819230E (pt) 2012-08-07
ATE555799T1 (de) 2012-05-15
ES2390317T3 (es) 2012-11-08
JP2008522974A (ja) 2008-07-03
EP1819230B1 (en) 2012-05-02
JP5204490B2 (ja) 2013-06-05
US20080069807A1 (en) 2008-03-20
US8105632B2 (en) 2012-01-31
WO2006062945A3 (en) 2006-12-07
DK1819230T3 (da) 2012-08-20
WO2006062945A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
PL1819230T3 (pl) Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
AU2018236800B2 (en) DNA-PK inhibitors
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
MX2019002564A (es) Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
MX2018005925A (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
PH12015501656A1 (en) Anti-il-33 antibodies and use thereof
PH12015502388A1 (en) Compositions and methods for altering second messenger signaling
NZ701121A (en) Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
DE602004013563D1 (de) Rantagonisten
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
EA201691235A1 (ru) Модифицированные серпины для лечения нарушений свертываемости крови
TW200734306A (en) Novel compounds, their preparation and use
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
MX2012013078A (es) Composiciones antimicrobianas liquidas de baja formacion de espuma, modificadas reologicamente, y sus metodos de uso.
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
WO2017007886A3 (en) Compositions for inhibiting dux4 gene expression and uses thereof
MX2022014220A (es) Inhibidores de calmodulin, inhibidores de chk2 e inhibidores de rsk para el tratamiento de trastornos ribosomales y ribosomatopias.
EA032472B9 (ru) Композиция для укладки волос
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2022007207A (es) Composiciones y metodos para tratar y prevenir la influenza.
MX2020006533A (es) Inhibidores del receptor activado por proteasa-2.
WO2018200615A3 (en) MODIFIED MRI CONTRAST PRODUCTS AND THEIR USE